BioCryst Pharma Withdraws Proposed Public Offering

BioCryst Pharmaceuticals Inc. (BCRX) said that it has withdrawn its proposed public offering. It believes that current market conditions are not conducive to an offering on terms that would be in the best interests of current stockholders.

BCRX closed Tuesday regular trading at $15.21 down $2.44 or 13.85%. But in the after-hours trading, the stock gained $1.54 or 10.16%.

The company said it is well capitalized, with cash, cash equivalents, restricted cash and investments of $222.8 million as of June 30, 2021.

The company believes current cash runway takes it into 2023. It is based on its expectations for revenue, operating expenses, and our option to access an additional $75 million from existing credit facility.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT